Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

被引：2

作者：

De Botton, Stephane ^{[1
]}

Yee, Karen ^{[2
]}

Recher, Christian ^{[3
]}

Wei, Andrew H. ^{[4
]}

Montesinos, Pau ^{[5
]}

Taussig, David ^{[6
]}

Pigneux, Arnaud ^{[7
]}

Braun, Thorsten ^{[8
]}

Curti, Antonio ^{[9
]}

Esteve, Jordi ^{[10
]}

Grove, Carolyn ^{[11
]}

Jonas, Brian A. ^{[12
]}

Khwaja, Asim ^{[13
,14
]}

Legrand, Olivier ^{[15
]}

Peterlin, Pierre ^{[16
]}

Sangerman, Montserrat Arnan ^{[17
]}

Blum, William G. ^{[18
]}

Cilloni, Daniela ^{[19
]}

Hiwase, Devendra ^{[20
]}

Jurcic, Joseph G. ^{[21
]}

Krauter, Jurgen ^{[22
]}

Thomas, Xavier ^{[23
]}

Watts, Justin ^{[24
]}

Yang, Jay ^{[25
]}

Xin, Zihao ^{[26
]}

Sedkov, Alex ^{[26
]}

Guichard, Sylvie ^{[26
]}

Sweeney, Jennifer ^{[26
]}

Marzac, Christophe ^{[27
]}

Cortes, Jorge E. ^{[28
]}

Fenaux, Pierre ^{[29
]}

机构：

[1] Inst Gustave Roussy, Dept Haematol, Villejuif, France

[2] Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Inst Univ Canc Toulouse Oncopole, Paris, France

[4] Alfred Hosp, Dept Haematol, Melbourne, Australia

[5] Hosp Univ Politecn La Fe Valencia, Dept Hematol, Valencia, Spain

[6] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

[7] Univ Bordeaux, Dept Hematol, Ctr HospUniv CHU Bordeaux, Bordeaux, France

[8] Paris XIII Univ, Hop Avicenne, AP HP, Bobigny, France

[9] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[10] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

[11] PathWest Sir Charles Gairdner Hosp, Dept Haematol, Dept Hlth, Nedlands, WA, Australia

[12] Univ Calif Davis, Div Hematol & Oncol, Dept Internal Med, Davis, CA USA

[13] Univ Coll London Hosp, London, England

[14] Univ Coll Canc Inst, London, England

[15] St Antoine Univ Hosp, Dept Hematol, Paris, France

[16] CHU Nantes, Serv Hematol Clin, Nantes, France

[17] IDIBELL, Inst Catala Oncol, Hosp Duran & Reynals, Clin Hematol Dept, Barcelona, Spain

[18] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[19] Univ Turin, Dept Clin & Biol Sci, Turin, Italy

[20] Royal Adelaide Hosp, Dept Haematol, Adelaide, SA, Australia

[21] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY USA

[22] Braunschweig Municipal Hosp, Dept Internal Med 3, Braunschweig, Germany

[23] Lyon Sud Univ Hosp, Hosp Civils Lyon, Dept Hematol, Pierre Benite, France

[24] Univ Miami, Dept Med, Leukemia Program, Sylvester Comprehens Canc Ctr, Miami, FL USA

[25] Karmanos Canc Inst, Dept Oncol, Detroit, MI USA

[26] Forma Therapeut Inc, Watertown, MA USA

[27] Univ Paris Saclay, Dept Biol pathol, Gustave Roussy, Villejuif, France

[28] Georgia Canc Ctr, Augusta, GA USA

[29] St Louis Hosp, Dept Haematol, Paris, France

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-144912

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2351

引用

页数：9

共 50 条

[1] Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia
Cortes, Jorge E.
Esteve, Jordi
Bajel, Ashish
Yee, Karen
Braun, Thorsten
De Botton, Stephane
Peterlin, Pierre
Recher, Christian
Thomas, Xavier
Watts, Justin
Sangerman, Montserrat Arnan
Curti, Antonio
Grove, Carolyn
Jonas, Brian A.
Lanza, Francesco
Legrand, Olivier
Montesinos, Pau
Patel, Prapti
Prebet, Thomas
Wang, Eunice S.
Polyanskaya, Olga
Brevard, Julie
Sweeney, Jennifer
Fenaux, Pierre
Wei, Andrew H.
BLOOD, 2021, 138
[2] Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia
De Botton, Stephane
Jonas, Brian Andrew
Ferrell, P. Brent
Chao, Mwe Mwe
Mims, Alice S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial
Cortes, Jorge E.
Fenaux, Pierre
Yee, Karen
Recher, Christian
Wei, Andrew H.
Montesinos, Pau
Taussig, David C.
Pigneux, Arnaud
Braun, Thorsten
Curti, Antonio
Grove, Carolyn
Jonas, Brian A.
Khwaja, Asim
Peterlin, Pierre
Polyanskaya, Olga
Sweeney, Jennifer
Brevard, Julie
Barrett, Emma
De Botton, Stephane
BLOOD, 2022, 140 : 6193 - 6196
[4] Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia
Wang, Eunice S.
Jonas, Brian A.
Watts, Justin M.
Jurcic, Joseph
Brent, Ferrell P., Jr.
Dinner, Shira N.
Yang, Jay
Seiter, Karen
Mims, Alice
Donnellan, William B.
Blum, William
Cortes, Jorge
BLOOD, 2023, 142
[5] Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax
Cortes, Jorge
Jurcic, Joseph
Baer, Maria R.
Blum, William
Brent, Ferrell P., Jr.
Jonas, Brian A.
Lee, Sangmin
Mims, Alice
Patel, Shyam Ajay
Schiller, Gary J.
Yang, Jay
Watts, Justin M.
BLOOD, 2023, 142
[6] Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.
De Botton, Stephane
Yee, Karen W. L.
Recher, Christian
Wei, Andrew
Montesinos, Pau
Taussig, David
Pigneux, Arnaud
Braun, Thorsten
Curti, Antonio
Esteve, Jordi
Grove, Carolyn
Jonas, Brian Andrew
Khwaja, Asim
Legrand, Ollivier
Peterlin, Pierre
Polyanskaya, Olga
Sweeney, Jennifer
Mohamed, Hesham
Cortes, Jorge E.
Fenaux, Pierre
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia
Watts, Justin M.
Shaw, Simon J.
Jonas, Brian A.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (11) : 1345 - 1353
[8] Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
de Botton, Stephane
Fenaux, Pierre
Yee, Karen
Recher, Christian
Wei, Andrew H.
Montesinos, Pau
Taussig, David C.
Pigneux, Arnaud
Braun, Thorsten
Curti, Antonio
Grove, Carolyn
Jonas, Brian A.
Khwaja, Asim
Legrand, Ollivier
Peterlin, Pierre
Arnan, Montserrat
Blum, William
Cilloni, Daniela
Hiwase, Devendra K.
Jurcic, Joseph G.
Krauter, Juergen
Thomas, Xavier
Watts, Justin M.
Yang, Jay
Polyanskaya, Olga
Brevard, Julie
Sweeney, Jennifer
Barrett, Emma
Cortes, Jorge
BLOOD ADVANCES, 2023, 7 (13) : 3117 - 3127
[9] Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment
De Botton, Stephane
Watts, Justin M.
Jonas, Brian Andrew
Chao, Mwe Mwe
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[10] Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
Cortes, Jorge E.
Roboz, Gail J.
Baer, Maria R.
Jonas, Brian A.
Schiller, Gary J.
Yee, Karen
Ferrell, P. Brent
Yang, Jay
Wang, Eunice S.
Blum, William G.
Mims, Alice
Tian, Hua
Sheppard, Aaron
de Botton, Stephane
Montesinos, Pau
Curti, Antonio
Watts, Justin M.
Olutasidenib Combination Therapy Study Grp
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)

← 1 2 3 4 5 →